Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Bobwinson Mar 20, 2018 12:04pm
220 Views
Post# 27746899

RE:RE:RE:NO PP IS COMING. THE COMPANY IS NOW FOR SALE

RE:RE:RE:NO PP IS COMING. THE COMPANY IS NOW FOR SALEWhat would happen if they get a royalty deal and wait for actual sales.

12% royalty on 1 billion in annual sales=$120million/yr in revs

Unlike most operating companies, the royalty income would mostly drop to the bottom line because there would be no sales staff, no big administration.  So what would you pay for a company generating $100 million/yr in net profits?  Divided by 260million shares= US$.38/share

Say $3.80-5.00.   X 260million shares = US$988million to 1.3 billion.potential market cap in a few years.

I say hold for the royalties and the cushy ride.  Also proving up the Hydrogen sulfide thesis means ATB=352 looks a LOT more promising and those royalties will pay for getting ATB-352 thru the trials without any more dilution.  

Why sell for C$200 million when US$1 billion is 3 years down the road plus whatever ATB-352 is worth by then.  
Bullboard Posts